Trial Profile

Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary)
Indications Thrombotic microangiopathy
Focus Registrational; Therapeutic Use
Sponsors Akari Therapeutics

Most Recent Events

16 Jul 2024 Primary measure 'Urine protein creatinine ratio less than or equal to 2 mg/mg' has been cancelled.
16 Jul 2024 Status changed from recruiting to discontinued. (Reason the study was stopped: The early termination of this study is a business decision following a portfolio reprioritization plan. The decision is not related to any Efficacy, Safety or Clinical concerns regarding Nomacopan/rVA576)
01 Apr 2024 According to an Akari media release, plans for initiation of the Part B study will be guided by the strategic pipeline assessment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com